1. Friman V., Winqvist O., Blimark C. et al. Secondary immunodeficiency in lymphoproliferative malignancies // Hematol. Oncol. 2016. Vol. 34, N 3. P. 121–132.
2. Colovic N., Bogdanovic A., MartinovicCemerikic V., Jankovic G. Prognostic significance of serum immunoglobulins in Bchronic lymphocytic leukaemia // Arch. Oncol. 2001. Vol. 9, N 2. P. 4.
3. Dhalla F., Lucas M., Schuh A., Bhole M., Jain R., Patel S.Y. et al. Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin? // J. Clin. Immunol. 2014. Vol. 34. P. 277–282.
4. Casulo C., Maragulia J., Zelenetz A.D. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections // Clin. Lymphoma Myeloma Leuk. 2012. Vol. 13, N 2. P. 106–111.
5. De Angelis F., Tosti M.E., Capria S. et al. Risk of secondary hypogammaglobulinaemia after rituximab and fludarabine in indolent nonHodgkin lymphomas: a retrospective cohort study // Leuk. Res. 2015. Vol. 39, N 12. P. 1382–1388.
6. Dhalla F., Misbah S.A. Secondary antibody deficiencies // Curr. Opin. Allergy Clin. Immunol. 2015. Vol. 15, N 6. P. 505–513.
7. Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment // Am. J. Hematol. 2015. Vol. 90, N 5. P. 446–460.
8. Shillitoe B., Hollingsworth R., Foster M., Garcez T., Guzman D., Edgar J.D. et al. Immunoglobulin use in immune deficiency in the UK: a report of the UKPID and National Immunoglobulin Databases // Clin. Med. (Lond.). 2018. Vol. 18, N 5. P. 364–370. DOI: https://doi.org/10.7861/clinmedicine.185364
9. Mallick R., Jolles S., Kanegane H., AgborTarh D., Rojavin M. Treatment satisfaction with subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency: a Pooled Analysis of Six Hizentra® Studies // J. Clin. Immunol. 2018. Vol. 38, N 8. P. 886–897. DOI: https://doi.org/10.1007/s1087501805623 Epub 2018 Nov 21.
10. Gale R.P., Chapel H.M., Bunch C., Rai K.R., Foon K., Courter S.G. et al.; Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative group for the study of immunoglobulin in chronic lymphocytic leukemia // N. Engl. J. Med. 1988. Vol. 319. P. 902–907.
11. Raanani P., GafterGvili A., Paul M., BenBassat I., Leibovici L., Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and metaanalysis // Leuk. Lymphoma. 2009. Vol. 50. P. 764–772.
12. Chapel H.M., Lee M., Hargreaves R., Pamphilon D.H., Prentice A.G. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateauphase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma // Lancet. 1994. Vol. 343. P. 1059–1063.
13. Compagno N., Malipiero G., Cinetto F., Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia // Front. Immunol. 2014. Vol. 5. P. 626.
14. Chapel H., Dicato M., Gamm H., Brennan V., Ries F., Bunch C. et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes // Br. J. Haematol. 1994. Vol. 88. P. 209–212.
15. Agostini C., Blau I.W., Kimby E., Plesner T. Prophylactic immunoglobulin therapy in secondary immune deficiency – an expert opinion // Expert Rev. Clin. Immunol. 2016. Vol. 12. P. 921–926.
16. European Medicines Agency. Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg). 2018. URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2018/07/WC500252345.pdf
17. Sewell W.A., Kerr J., BehrGross M.E., Peter H.H.; Kreuth Ig Working Group. European consensus proposal for immunoglobulin therapies // Eur. J. Immunol. 2014. Vol. 44. P. 2207–2214.
18. Perez E.E., Orange J.S., Bonilla F., Chinen J., Chinn I.K., Dorsey M. et al. Update on the use of immunoglobulin in human disease: a review of evidence // J. Allergy Clin. Immunol. 2017. Vol. 139. P. S1–S46.
19. Tausch E., Stilgenbauer S. Chronic lymphocytic leukemia: current standards and novel approaches // Internist (Berl). 2014. Vol. 55, N 12. P. 1400, 1402–1404, 1406–1409. DOI: https://doi.org/10.1007/s0010801435560
20. Schuh A.H., ParryJones N., Appleby N., Bloor A., Dearden C.E., Fegan C. et al. Guideline for the treatment of chronic lymphocytic leukaemia: a British Society for Haematology Guideline // Br. J. Haematol. 2018.Vol. 182, N 3. P. 344–359. DOI: https://doi.org/10.1111/bjh.15460 Epub 2018 Jul 15.
21. Jolles S., Chapel H., Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach // Clin. Exp. Immunol. 2017. Vol. 188, N 3. P. 333–341.
22. Windegger T.M., Nghiem S., Nguyen K.H., Fung Y.L., Scuffham P.A. Primary immunodeficiency disease: a costutility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia // Blood Transfus. 2020. Vol. 18, N 2. P. 96–105.
23. Oscier D., Dearden C., Eren E., Erem E., Fegan C., Follows G. et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia // Br. J. Haematol. 2012. Vol. 159, N 5. P. 541–564.
24. Wolf H.M., Thon V., Litzman J., Eibl M.M. Detection of impaired IgG antibody formation facilitates the decision on early immunoglobulin replacement in hypogammaglobulinemic patients // Front. Immunol. 2015. Vol. 6. P. 32.
25. Kivity S., Katz U., Daniel N., Nussinovitch U., Papageorgiou N., Shoenfeld Y. Evidence for the use of intravenous immunoglobulins – a review of the literature // Clin. Rev. Allergy Immunol. 2010. Vol. 38, N 2–3. P. 201–269.